{"id":"W4386329445","doi":"10.1186/s13058-023-01701-9","title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Internal medicine; Breast cancer; Oncology; Population; Cancer; Placebo; Letrozole; Progression-free survival; Proportional hazards model; Chemotherapy; Tamoxifen; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003140431,0.0006700037,0.001416231,0.0003895209,0.0002668432,0.00100137,0.0006022307,0.0006194894,0.00325465],"category_scores_gemma":[0.001861518,0.0001766777,0.001664115,0.0004790602,0.0002728095,0.0005534645,0.0006230557,0.001413798,0.0003878429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007034618,"about_ca_system_score_gemma":0.0008102703,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001409892,"about_ca_topic_score_gemma":0.006128796,"domain_scores_codex":[0.9993221,0.0003543448,0.00004117967,0.00009910903,0.0001035571,0.0000797785],"domain_scores_gemma":[0.9991121,0.0002034479,0.0002901071,0.00009154832,0.00006735534,0.0002354287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7657993,0.002129677,0.05211766,0.003142931,0.01055335,0.0002753124,0.0002820821,0.007879242,0.006394874,0.0007041892,0.02347809,0.1272434],"study_design_scores_gemma":[0.3720468,0.1095245,0.4359851,0.0008362007,0.02347236,0.001005369,0.0002852735,0.005839122,0.002971508,0.002400552,0.04544879,0.0001844156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9526201,0.0184084,0.0006584987,0.001246461,0.0002764835,0.0006696861,0.01894142,0.00009345866,0.00708545],"genre_scores_gemma":[0.9594253,0.003946021,0.0006741691,0.001285626,0.0003048154,0.001459296,0.02953708,0.00003528404,0.003332523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00325465,"threshold_uncertainty_score":0.01660842,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05336560724581937,"score_gpt":0.374452246573516,"score_spread":0.3210866393276967,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}